» Articles » PMID: 14742319

Id-1-induced Raf/MEK Pathway Activation is Essential for Its Protective Role Against Taxol-induced Apoptosis in Nasopharyngeal Carcinoma Cells

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2004 Jan 27
PMID 14742319
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Increasingly, evidence supports the function of the helix-loop-helix protein Id-1 (inhibitor of differentiation/DNA binding-1) as an oncogene. Over-expression of Id-1 is not only observed in many types of human cancer but its expression levels have been correlated with cancer progression. However, little is known about the molecular mechanisms responsible for the function of Id-1. Recently, we and others reported that Id-1-induced cell proliferation was mediated through a Raf/MEK signalling pathway. In this study, we investigated if ectopic Id-1 expression in nasopharyngeal carcinoma cells had any protective effect on taxol-induced death, which is also regulated through Raf/MEK pathway. Using four stable Id-1 transfectant clones, we found that exogenous Id-1 expression led to phosphorylation of Raf-1 and MEK1/2 kinases, which was associated with resistance to taxol. Treatment of the Id-1 expressing cells with a MEK inhibitor, PD098059, resulted in an increased taxol-induced apoptosis rate in Id-1 transfectants compared with the vector control. In addition, the fact that the taxol-induced apoptosis rate, down-regulation of Bcl-2 and up-regulation of Bax were suppressed by PD098059 treatment in Id-1 expressing cells indicates that the Id-1 induced cellular protection against apoptosis is mediated through Raf/MEK signalling pathways. Our results suggest that Id-1 may be an upstream regulator of the Raf/MEK signalling pathway, which plays an essential role in protection against taxol-induced apoptosis. Our evidence also indicates a novel treatment strategy to increase anticancer drug-induced apoptosis through inactivation of the Id-1 protein.

Citing Articles

Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells.

Phadte P, Bishnu A, Dey P, M M, Mehrotra M, Singh P J Exp Clin Cancer Res. 2024; 43(1):222.

PMID: 39123206 PMC: 11316295. DOI: 10.1186/s13046-024-03147-z.


The antipsychotic drug pimozide promotes apoptosis through the RAF/ERK pathway and enhances autophagy in breast cancer cells.

Jiang G, Zhou X, Hu Y, Tan X, Wang D, Yang L Cancer Biol Ther. 2024; 25(1):2302413.

PMID: 38356266 PMC: 10878017. DOI: 10.1080/15384047.2024.2302413.


Methylation of CpG Sites as Biomarkers Predictive of Drug-Specific Patient Survival in Cancer.

Neary B, Lin S, Qiu P Cancer Inform. 2022; 21:11769351221131124.

PMID: 36340286 PMC: 9634212. DOI: 10.1177/11769351221131124.


Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.

Gangapuram M, Mazzio E, Redda K, Soliman K Int J Mol Sci. 2021; 22(14).

PMID: 34299315 PMC: 8306781. DOI: 10.3390/ijms22147694.


Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells.

Zhang X, Ling M, Feng H, Wong Y, Tsao S, Wang X Br J Cancer. 2021; 124(10):1748.

PMID: 33723401 PMC: 8110982. DOI: 10.1038/s41416-021-01322-z.